Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Biotinylated Human HVEM / TNFRSF14, Fc Tag, Avi Tag (Avitag™), 200 µg  

Recombinant Biotinylated Human HVEM / TNFRSF14, Fc Tag, Avi Tag (Avitag™), 200 µg

MABSol® Biotinylated Human HVEM / TNFRSF14, expressed from human HEK293 cells, Fc-Tag, Avi tag (Avitag™)

Synonym:recombinant, human, biotinylated, protein, TNFRSF14,ATAR,HVEA,HVEM,LIGHTR,TR2,CD270

More details

HV4-H82F1-200

1 380,00 €

Background
Herpesvirus entry mediator (HVEM) is also known as TNFRSF14, TR2 (TNF receptorlike molecule) and ATAR (another TRAF associated receptor), is a type I membrane protein belonging to the TNF/NGF receptor superfamily. HVEM expression has been detected in peripheral blood T cells, B cells, monocytes and in various tissues enriched in lymphoid cells. The extracellular domain of HVEM has been shown to interact directly with the herpes simplex virus envelope glycoprotein D (gD). Two TNF superfamily ligands, including the secreted TNFβ (lymphotoxin α) and the membrane protein LIGHT (lymphotoxins, exhibits inducible expression, and competes with HSV glycoprotein D for HVEM, a receptor expressed by T lymphocytes), have been shown to be the cellular ligands for HVEM. Besides HVEM, LIGHT can also interact with LTβR, the receptor for lymphotoxin αβ heterotrimer. The role of the HVEM LIGHT /LTβ receptor ligand pair in immune function and herpesvirus pathobiology remains to be elucidated.

Source
Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.

Source
MABSol® Biotinylated Human HVEM / TNFRSF14, Fc Tag (HV4-H82F1) is expressed from human HEK293 cells. It contains AA Leu 39 - Val 202 (Accession # NP_003811).
Predcited N-terminus: Leu 39

Molecular Characterization
This protein carries a human IgG1 Fc fragment at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 45.8 kDa. The protein migrates as 55-66 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.

Biotinylation
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22µm filtered solution in 50 mM tris, 100 mM glycine (pH7.5) with Trehalose as protectant.
Contact us for customized product form or formulation.

Reconstitution
Reconstitute at 250 μg/mL in sterile deionized water. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the COA.

Bioactivity
Measured by its binding ability in a functional ELISA against immobilized ActiveMax® Human TNF-beta (Cat# TNB-H5214, 1 μg/well). The linear range is 0.6-10 μg/mL.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. No activity loss is observed after storage at: 4-8°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution.

Limited Use License
The Biotin AviTag technology is covered by U.S. Pat. No: 5,874,239 and includes any and all materials, methods, kits and related derivatives claimed by this patent. The purchase of the Acrosbiosystems’s Avitag™ proteins confers to the purchaser the limited right to use the Avitag™ technology for non-commercial, or research use, or for purposes of evaluating the Avitag™ technology.

References

(1) Hsu H., et al., 1997, J. Biol. Chem., 272:13471.
(2) Mauri, D.N. et al., 1998, Immunity 8:21.
(3) Montgomery, R.I. et al., 1996, Cell 87:427.
(4) Cheung,T.C.et al., 2005, Proc.Natl.Acad.Sci.USA102:13218-23.